CA
NZ
UK
AU
IND
US
BioAge Labs (NASDAQ:BIOA), a clinical-stage biopharmaceutical company, announced dosing of the first participant in QUELL-DME, a controlled study evaluating oral BGE-102 in adults with diabetic macular edema. The trial assigns participants to different treatment approaches: one group receives anti-VEGF therapy with an oral placebo, …
GRAIL (NASDAQ:GRAL) has completed its premarket approval submission to the FDA for Galleri, its multi-cancer early detection test, building on positive topline results already disclosed from the registrational NHS-Galleri trial, a randomized controlled study conducted within England's National Health Service, and from the PATHFINDER …
Lumexa Imaging Holdings (NASDAQ:LMRI) has drawn initiating coverage with Buy or Strong Buy ratings from a wide roster of major banks, including Jefferies, Wells Fargo, Raymond James, William Blair, Leerink and Barclays, several citing the company's strong local market positions and the pace of …
On October 5, 2026 at 7:00 a.m. ET, Alector announced an exclusive global license giving Genentech, a member of the Roche Group, rights to AL050, a brain-penetrant enzyme replacement therapy for Parkinson's disease built on the Alector Brain Carrier delivery platform. The terms are …
● No confirmed company-specific release was identified for the session.
● Praxis Precision Medicines (PRAX) shares fell 4.04% to close at $283.56 on Monday, October 5, 2026.
● No confirmed company-specific news was identified for the session.
● The confirmed record shows no company-specific release for Scholar Rock during the session.
The FDA is reviewing Savara'sBiologicslicense application for MOLBREEVI, the trade name for molgramostim inhalation solution, under Priority Review, with a target action date of November 22, 2026 following a three-month extension from an original August date. The FDA said the company's responses to recent …
Jefferies lowered its RxSight (NASDAQ:RXST) price target to USD 5.75 per share, continuing a pattern seen across much of 2026 as multiple firms, including UBS, Stifel, Bank of America and Wells Fargo, have repeatedly trimmed their targets following a stretch of sales that missed …
Please wait processing your request...